Intravenous magnesium sulfate: new method in prevention of contrast-induced nephropathy in primary percutaneous coronary intervention
- 5 December 2014
- journal article
- research article
- Published by Springer Nature in International Urology and Nephrology
- Vol. 47 (3) , 521-525
Abstract
Contrast-induced acute kidney injury (CI-AKI) is an adverse consequence of percutaneous coronary interventions which results in significant morbidity and mortality and adds to the costs of diagnostic and interventional cardiology procedures. Various pathophysiological mechanisms have been proposed for CI-AKI and various agents tested for its prevention. There is currently a general agreement that adequate pre-procedural hydration constitutes the cornerstone of prevention, yet there are reports of the use of some other agents with various efficacies. We prospectively tested IV magnesium sulfate (Mg) for CI-AKI prevention. This study is a prospective, randomized, open-labeled, single-center clinical trial. We randomly assigned 122 consecutive patients to two groups. The first group was the control group with routine treatment (n = 64), and second group was the study group with routine treatment plus IV magnesium sulfate 1 g just before the procedure (n = 62). Serum creatinine was measured before the procedure and 2 days after the procedure. The primary end point was the occurrence of CI-AKI within 48 h. CI-AKI was defined as 0.5 mg/dl or more increase in serum creatinine or 25 % or more increase above baseline serum creatinine. There was no difference in definition if both of these parameters were present. The control and study groups were comparable in the overall predicted risk of CI-AKI. Also, the type and volume of the contrast were not significantly different between the two groups. Following angioplasty, CI-AKI occurred in 17 (26.6 %) patients in the control group and nine (14.5 %) patients in the study group; there was a significant reduction in CI-AKI in the study group (P = 0.01). Additionally, there was no mortality or a need for hemodialysis in either group. In primary PCI patients, the prophylactic use of intravenous Mg can be recommended to be added to traditional hydration for CI-AKI prevention.Keywords
This publication has 21 references indexed in Scilit:
- A randomized comparison of 1-h sodium bicarbonate hydration versus standard peri-procedural saline hydration in patients with chronic kidney disease undergoing intravenous contrast-enhanced computerized tomographyNephrology Dialysis Transplantation, 2014
- N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trialTrials, 2009
- Sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of 17 randomized trialsInternational Urology and Nephrology, 2009
- Protective effect of pentoxifylline on contrast induced nephropathy.2008
- Sodium Bicarbonate vs Sodium Chloride for the Prevention of Contrast Medium–Induced Nephropathy in Patients Undergoing Coronary AngiographyJAMA, 2008
- Failure of ascorbic acid to prevent contrast-media induced nephropathy in patients with renal dysfunctionClinical Nephrology, 2007
- Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN)International Journal of Cardiology, 2006
- The role of theophylline in contrast-induced nephropathy: a case-control studyNephrology Dialysis Transplantation, 2002
- Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiencyThe American Journal of Cardiology, 1999
- Oxygen free radicals and contrast nephropathyAmerican Journal of Kidney Diseases, 1998